EATG ┬╗ The unexpected success of NRTIs in second-line treatment

The unexpected success of NRTIs in second-line treatment

Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. A study, published in The Lancet Infectious Diseases, assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings.

The full study is available here.

An accompanying comment can be accessed here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn